CJC-1295 (No DAC)

CJC-1295 no DAC peptide Canada: a synthetic growth hormone-releasing hormone (GHRH) analog also known as Modified GRF(1-29). This 29-amino acid peptide is available from Maple Research Labs with greater than 98% HPLC-verified purity and batch-specific COA on every order.

Product Specifications

• Alternative Names: Modified GRF(1-29), Mod GRF 1-29, CJC-1295 without DAC
• Sequence Length: 29 amino acids (modified GHRH fragment)
• Key Modifications: D-Ala2, Gln8, Ala15, Leu27 substitutions
• Purity: >98% (HPLC verified)
• Form: Lyophilized powder
• Quantity: 5mg per vial

CJC-1295 No DAC Peptide Canada Research Summary

CJC-1295 without DAC (Modified GRF 1-29) is a synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH) with four amino acid substitutions designed to improve metabolic stability. The CJC-1295 no DAC peptide Canada product contains modifications at positions 2, 8, 15, and 27 that protect against enzymatic degradation while maintaining GHRH receptor binding activity.

Unlike CJC-1295 with DAC (Drug Affinity Complex), the no-DAC version does not incorporate the maleimidopropionic acid-lysine linker that enables albumin binding. This results in a shorter biological half-life but produces acute, pulsatile GH release patterns more closely resembling physiological GHRH signaling, which is preferred in certain research protocols.

Mechanism of Action Research

Modified GRF(1-29) acts through the GHRH receptor (GHRHR) on anterior pituitary somatotroph cells. Receptor binding activates adenylyl cyclase, increasing intracellular cAMP and triggering calcium-dependent GH exocytosis. The resulting GH release follows a pulsatile pattern characteristic of GHRH-mediated secretion, distinguishing it from the sustained elevation produced by the DAC-modified version.

The four amino acid substitutions address specific vulnerability sites in native GHRH(1-29). D-Ala2 protects against DPP-IV cleavage at the N-terminus. Gln8 eliminates asparagine-mediated deamidation. Ala15 and Leu27 further enhance proteolytic resistance. These modifications collectively extend the peptide’s biological activity while preserving receptor selectivity.

Research has examined Modified GRF(1-29) both alone and in combination with GHSR agonists such as ipamorelin and GHRP-6. Published studies have investigated whether simultaneous GHRH receptor and ghrelin receptor stimulation produces synergistic effects on GH secretion amplitude and frequency in animal models.

Preclinical Study Summary

CJC-1295 without DAC has been studied in neuroendocrine research examining GH axis regulation, pulsatile secretion patterns, and GHRH receptor pharmacology. Comparative studies with the DAC-modified version have characterized differences in pharmacokinetics, GH release dynamics, and IGF-1 axis stimulation.

All findings are from preclinical research. No therapeutic claims are made.

References

• Ionescu M, Bhatt DL. Prolonged GHRH analog administration and release of growth hormone. J Clin Endocrinol Metab. 2006 (PubMed)

CJC-1295 No DAC Peptide Canada Quality Assurance

Every batch of CJC-1295 no DAC peptide Canada from Maple Research Labs undergoes independent third-party HPLC analysis confirming purity exceeding 98%. Each order includes a batch-specific COA with retention time data, purity percentage, and mass spectrometry identity confirmation. The four amino acid modifications are verified through sequence analysis on every batch.

Storage and Handling

Store lyophilized at -20C. Reconstituted at 2-8C, use within 14 days. Avoid freeze-thaw cycles.

Shipping

Ships same-day from our Canadian facility. Temperature-controlled packaging included.

For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.

Related Research Articles

• Ipamorelin vs CJC-1295: GHRP vs GHRH Research
• Ipamorelin vs Tesamorelin: GHS Research Differences
• Certificates of Analysis (COA) Documentation
• Browse All Research Peptides

Frequently Asked Questions

What is the CAS number for CJC-1295 No DAC?

The CAS registry number for CJC-1295 is 863288-34-0. The “No DAC” variant lacks the Drug Affinity Complex modification.

What is CJC-1295 No DAC purity?

Batch MRL-CND-0326 tested at 98.5% purity by independent HPLC at Janoshik Analytical.

How does CJC-1295 No DAC differ from the DAC version?

CJC-1295 without DAC (also called Mod GRF 1-29) is a 29-amino acid GHRH analog with a shorter research half-life. The DAC version includes a Drug Affinity Complex that extends the half-life in research models.